<DOC>
	<DOCNO>NCT00418249</DOCNO>
	<brief_summary>The primary objective study assess safety efficacy topical AS101 treatment Female Androgenetic Alopecia ( FAGA ) menopause woman .</brief_summary>
	<brief_title>Topical AS101 Treatment FAGA ( Female Androgenetic Alopecia ) Menopause Women</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<criteria>Women menopause , 50 year age . Clinically diagnose AGA , accord Ludwig scale III . Women treat chronic medication . Use Minoxidil within 3 month prior enter study . Women underwent hair transplantation . Use drug androgenic antiandrogenic effect . Any type hair loss .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Androgenetic Alopecia</keyword>
	<keyword>Telogen effluvium</keyword>
	<keyword>Chronic telogen effluvium</keyword>
	<keyword>Menopause</keyword>
	<keyword>Female Androgenetic Alopecia ( FAGA )</keyword>
</DOC>